Intralesional adenovirus-mediated interleukin-2 gene transfer for advanced solid cancers and melanoma

Molecular Therapy

Volumn 16, Issue 5, 2008, Pages 985-994

  Dummer, Reinhard ^a   Rochlitz, Christoph ^b   Velu, Thierry ^c   Acres, Bruce ^d   Limacher, Jean Marc ^d   Bleuzen, Pascal ^d   Lacoste, Gisèle ^d   Slos, Philippe ^d   Romero, Pedro ^e   Urosevic, Mirjana ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b UNIVERSITY HOSPITAL BASEL   (Switzerland)

^c ERASME HOSPITAL   (Belgium)

^d TRANSGENE S A   (France)

^e LUDWIG INSTITUTE FOR CANCER RESEARCH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; DACARBAZINE; INTERLEUKIN 12; INTERLEUKIN 2; TG 1024;

ADULT; ADVANCED CANCER; AGED; ARTICLE; ASTHENIA; BILE DUCT CARCINOMA; BLADDER CARCINOMA; BRAIN METASTASIS; CANCER PAIN; CD8+ T LYMPHOCYTE; CHEMOTHERAPY INDUCED EMESIS; CHILL; CLINICAL ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; COLLAPSE; COLON ADENOCARCINOMA; CONSTIPATION; CYTOKINE RELEASE; DIARRHEA; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG FATALITY; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; FLU LIKE SYNDROME; GENE TRANSFER; HEAD AND NECK CANCER; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INFLAMMATION; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; INJECTION SITE REACTION; INJECTION SITE SWELLING; INTRADUCTAL CARCINOMA; KIDNEY CANCER; LIPOSARCOMA; LYMPHOCYTIC INFILTRATION; LYMPHOCYTOPENIA; MALE; MELANOMA; MULTICENTER STUDY; NAUSEA; NEUROECTODERM TUMOR; OPEN STUDY; OUTCOME ASSESSMENT; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PROTEIN BLOOD LEVEL; REPEATED DRUG DOSE; SKIN CARCINOMA; SOLID TUMOR; SQUAMOUS CELL CARCINOMA; STOMACH PAIN; THROMBOCYTOPENIA; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY;

ADENOVIRIDAE;

EID: 42549165017     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2008.32     Document Type: Article

References (32)

1. AA Rayner EA Grimm MT Lotze DJ Wilson SA Rosenberg Lymphokine-activated killer (LAK) cell phenomenon. IV. Lysis by LAK cell clones of fresh human tumor cells from autologous and multiple allogeneic tumors J Natl Cancer Inst 75 1985 67 75
2. SA Rosenberg JJ Mulé PJ Spiess CM Reichert SL Schwarz Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high-dose recombinant interleukin 2 J Exp Med 161 1985 1169 1188
3. G Fyfe RI Fisher SA Rosenberg M Sznol DR Parkinson AC Louie Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy J Clin Oncol 13 1995 688 696
4. SA Rosenberg MT Lotze LM Muul S Leitman AE Chang SE Ettinghausen Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer N Engl J Med 313 1985 1485 1492
5. CL Addison T Braciak R Ralston WJ Muller J Gauldie FL Graham Intratumoral injection of an adenovirus expressing interleukin 2 induces regression and immunity in a murine breast cancer model Proc Natl Acad Sci USA 92 1995 8522 8526
6. H Haddada T Ragot L Cordier MT Duffour M Perricaudet Adenoviral interleukin-2 gene transfer into P815 tumor cells abrogates tumorigenicity and induces antitumoral immunity in mice Hum Gene Ther 4 1993 703 711
7. AK Stewart NJ Lassam IC Quirt DJ Bailey LE Rotstein M Krajden Adenovector-mediated gene delivery of interleukin-2 in metastatic breast cancer and melanoma: results of a phase 1 clinical trial Gene Ther 6 1999 350 363
8. S Trudel J Trachtenberg A Toi J Sweet ZH Li M Jewett A phase I trial of adenovector-mediated delivery of interleukin-2 (AdIL-2) in high-risk localized prostate cancer Cancer Gene Ther 10 2003 755 763
9. R Dummer JC Hassel F Fellenberg S Eichmüller T Maier P Slos Adenovirus-mediated intralesional interferon- γ gene transfer induces tumor regressions in cutaneous lymphomas Blood 104 2004 1631 1638
10. SE Raper M Yudkoff N Chirmule GP Gao F Nunes ZJ Haskal A pilot study of in vivo liver-directed gene transfer with an adenoviral vector in partial ornithine transcarbamylase deficiency Hum Gene Ther 13 2002 163 175
11. M Othman A Labelle I Mazzetti HS Elbatarny D Lillicrap Adenovirus-induced thrombocytopenia: the role of von Willebrand factor and P-selectin in mediating accelerated platelet clearance Blood 109 2007 2832 2839
12. M Urosevic K Fujii B Calmels E Laine N Kobert B Acres Type I interferon innate response to adenoviral vector contributes to the regression of cutaneous lymphomas following adenovirus-mediated interferon- γ gene transfer J Clin Invest 2007 in the press
13. M Urosevic R Dummer Immunotherapy for nonmelanoma skin cancer: does it have a future? Cancer 94 2002 477 485
14. R Motley P Kersey C Lawrence British Association of Dermatologists; British Association of Plastic Surgeons, Multiprofessional guidelines for the management of the patient with primary cutaneous squamous cell carcinoma Br J Plast Surg 56 2003 85 91
15. TH Nguyen DQ Ho Nonmelanoma skin cancer Curr Treat Options Oncol 3 2002 193 203
16. E Galanis EM Hersh AT Stopeck R Gonzalez P Burch C Spier Immunotherapy of advanced malignancy by direct gene transfer of an interleukin-2 DNA/DMRIE/DOPE lipid complex: phase I/II experience J Clin Oncol 17 1999 3313 3323
17. P Radny UM Caroli J Bauer T Paul C Schlegel TK Eigentler Phase II trial of intralesional therapy with interleukin-2 in soft-tissue melanoma metastases Br J Cancer 89 2003 1620 1626
18. MB Atkins Cytokine-based therapy and biochemotherapy for advanced melanoma Clin Cancer Res 12 7 Pt 2 2006 2353s 2358s
19. G Parmiani C Castelli M Santinami L Rivoltini Melanoma immunology: past, present and future Curr Opin Oncol 19 2007 121 127
20. JW Eklund TM Kuzel A review of recent findings involving interleukin-2-based cancer therapy Curr Opin Oncol 16 2004 542 546
21. JC Yang SA Rosenberg An ongoing prospective randomized comparison of interleukin-2 regimens for the treatment of metastatic renal cell cancer Cancer J Sci Am 3 suppl. 1 1997 S79 S84
22. R Kim M Emi K Tanabe K Arihiro Tumor-driven evolution of immunosuppressive networks during malignant progression Cancer Res 66 2006 5527 5536
23. U Keilholz P Martus C Scheibenbogen Immune monitoring of T-cell responses in cancer vaccine development Clin Cancer Res 12 7 Pt 2 2006 2346s 2352s
24. T Boon PG Coulie BJ Van den Eynde P van der Bruggen Human T cell responses against melanoma Annu Rev Immunol 24 2006 175 208
25. JC Yang J Abad R Sherry Treatment of oligometastases after successful immunotherapy Semin Radiat Oncol 16 2006 131 135
26. C Grande JL Firvida V Navas J Casal Interleukin-2 for the treatment of solid tumors other than melanoma and renal cell carcinoma Anticancer Drugs 17 2006 1 12
27. Z Krastev V Koltchakov B Tomov JW Koten Non-melanoma and non-renal cell carcinoma malignancies treated with interleukin-2 Hepatogastroenterology 50 2003 1006 1016
28. N Bessis FJ GarciaCozar MC Boissier Immune responses to gene therapy vectors: influence on vector function and effector mechanisms Gene Ther 11 suppl. 1 2004 S10 S17
29. DA Muruve The innate immune response to adenovirus vectors Hum Gene Ther 15 2004 1157 1166
30. A Franzke D Peest M Probst-Kepper J Buer GI Kirchner G Brabant Autoimmunity resulting from cytokine treatment predicts long-term survival in patients with metastatic renal cell cancer J Clin Oncol 17 1999 529 533
31. + T-cell immunity and NK activity Cancer Gene Ther 8 2001 321 332
32. + T cells in a large proportion of human histocompatibility leukocyte antigen (HLA)-A2 individuals J Exp Med 190 1999 705 715